Key Points
- Jeffrey Smith, Zymeworks' EVP, sold 9,310 shares on Jan. 12 at an average price of $22.67 for about $211,058, cutting his position by 25.85% to 26,708 shares, per an SEC filing.
- The company reported Q3 EPS of ($0.26), beating estimates by $0.02 but missing on revenue ($27.61M vs. $33.69M expected); shares trade around $23 with a 52‑week range of $9.03–$28.49.
- Analysts are broadly bullish — consensus rating Buy with an average target of $32.82 and several firms raising targets up to $40 — and institutional investors own roughly 92.9% of the stock.
Zymeworks Inc. (NYSE:ZYME - Get Free Report) EVP Jeffrey Smith sold 9,310 shares of the business's stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $22.67, for a total value of $211,057.70. Following the completion of the sale, the executive vice president directly owned 26,708 shares of the company's stock, valued at $605,470.36. This represents a 25.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Zymeworks Stock Performance
Shares of NYSE ZYME opened at $23.16 on Tuesday. The business's 50-day simple moving average is $24.32 and its 200-day simple moving average is $18.42. Zymeworks Inc. has a 52 week low of $9.03 and a 52 week high of $28.49. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of -15.44 and a beta of 1.30.
Zymeworks (NYSE:ZYME - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%.The firm had revenue of $27.61 million during the quarter, compared to analysts' expectations of $33.69 million. During the same quarter in the prior year, the business earned ($0.39) earnings per share. The company's revenue was up 72.6% on a year-over-year basis. As a group, equities research analysts forecast that Zymeworks Inc. will post -1.39 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of ZYME. Optiver Holding B.V. acquired a new position in shares of Zymeworks in the 3rd quarter valued at $26,000. Quarry LP acquired a new position in Zymeworks in the third quarter worth about $50,000. Tower Research Capital LLC TRC lifted its stake in Zymeworks by 29.6% during the second quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company's stock worth $62,000 after purchasing an additional 1,131 shares during the period. CWM LLC lifted its stake in Zymeworks by 272.8% during the second quarter. CWM LLC now owns 8,570 shares of the company's stock worth $108,000 after purchasing an additional 6,271 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in Zymeworks by 157.7% during the second quarter. BNP Paribas Financial Markets now owns 10,307 shares of the company's stock valued at $129,000 after purchasing an additional 6,307 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on ZYME shares. Citigroup initiated coverage on shares of Zymeworks in a research report on Wednesday, December 3rd. They set an "outperform" rating for the company. Wells Fargo & Company raised Zymeworks from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $25.00 to $33.00 in a research report on Friday, December 12th. Leerink Partners set a $37.00 target price on Zymeworks in a report on Monday, November 17th. Truist Financial assumed coverage on Zymeworks in a report on Wednesday, December 17th. They set a "buy" rating and a $40.00 price target for the company. Finally, B. Riley restated a "buy" rating and issued a $40.00 price objective (up previously from $30.00) on shares of Zymeworks in a research note on Friday, November 21st. Eleven analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $32.82.
Read Our Latest Report on ZYME
Zymeworks Company Profile
(
Get Free Report)
Zymeworks Inc is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, with a focus on the discovery, development and commercialization of multifunctional biotherapeutics. Founded in 2003, the company applies proprietary protein engineering platforms to create novel antibody and protein-based therapies targeting oncology and other serious diseases. Zymeworks is publicly traded on the New York Stock Exchange under the symbol ZYME.
The company's core technology platforms include Azymetric®, which enables the design of bispecific antibodies capable of engaging two distinct targets simultaneously, and the EFECT™ platform for fine-tuning antibody-drug conjugate properties.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
